ArticleJHEP reports : innovation in hepatology2026

EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE.

Margarida Augusto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.